• News
  • SAN DIEGO
  • BioTech

Seragon appoints N. Anthony Coles to board

San Diego-based Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, has appointed N. Anthony Coles, M.D., to the company's board of directors.

Coles brings nearly 30 years of experience in the health care, biotechnology and pharmaceutical industries. Most recently, he served as president, CEO and chairman of the board of Onyx Pharmaceuticals, a global biopharmaceutical company that was acquired by Amgen in October 2013.

Prior to joining Onyx in 2008, Coles was president, CEO, and a member of the board of directors of NPS Pharmaceuticals Inc. Before that, he was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb, and from 1992 until 1996 he also held a number of positions of increasing responsibility at Merck & Co. Inc.

Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a cardiovascular research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University.

Dr. Coles is a member of the board of directors of McKesson Corp. He is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. Coles also serves as a member of the board of the U.S. Olympic and Paralympic Foundation.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.